Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Leukemia
Leukemia
Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia
Caroline Helwick
,
Caroline Helwick
,
Caroline Helwick
Play Video
In the News
,
Leukemia
November 4, 2019 — Oncology News & Updates
Play Video
Leukemia
Obinutuzumab Could Give Rituximab a Run for Its Money in Relapsed Indolent NHL
Play Video
Leukemia
Oral Azacitidine Extends Survival in Acute Myeloid Leukemia, Regardless of MRD Status, in Patients in Remission After Chemotherapy
Wayne Kuznar
Wayne Kuznar
Play Video
FDA Approvals
,
Leukemia
,
Select Drug Profiles
Oral Onureg First Drug Approved for Adults with AML in Remission
Play Video
Leukemia
Pediatric Regimen a New Standard for Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Play Video
Leukemia
Ponatinib Overcomes Hard-to-Treat T315I Mutation in Patients with CML/ALL
Neil Canavan
,
Neil Canavan
Play Video
Leukemia
Ponatinib, a Tyrosine Kinase Inhibitor, Active in Patients with Relapsed or Refractory Chronic Myeloid Leukemia and BCR-ABL T315I Mutation
Charles Bankhead
Play Video
Leukemia
Pracinostat-Azacitidine Combination Generates Responses in Older Adults with Acute Myeloid Leukemia
Wayne Kuznar
Play Video
Leukemia
Promising Drugs in the Pipeline for Leukemia and Myelodysplastic Syndromes
Wayne Kuznar
Play Video
3
4
5
6
7
Page 6 of 7
Results 51 - 60 of 70